Skip to main content

Table 1 Participants characteristics (N = 196)

From: Nutritional risk and nutritional status in hospitalized older adults living with HIV in Shenzhen, China: a cross-sectional study

Characteristics n (%), M ± SD (IQR)
Having no nutritional risk
n1 = 125
Having nutritional risk
n2 = 71
Full Sample
N = 196
Age 56.58 ± 6.52 (50–83) 61.67 ± 9.26 (50–85) 58.41 ± 7.99 (50–85)
Gender
 Male 112 (57.14) 62 (31.63) 174 (88.77)
 Female 13 (6.63) 9 (4.59) 22 (11.22)
Ethnicity
 Han 125 (63.78) 69 (35.20) 194 (98.98)
 Minority 0 (0.00) 2 (1.02) 2 (1.02)
Education attainment
 Primary school of below 28 (14.29) 21 (10.71) 49 (25.00)
 Secondary school 48 (24.49) 29 (14.80) 77 (39.29)
 Post-secondary 40 (20.41) 19 (9.69) 59 (30.10)
 University or above 9 (4.59) 2 (1.02) 11 (5.61)
Marital status
 Married 113 (57.65) 57 (29.08) 170 (86.73)
 Single 12 (6.12) 14 (7.14) 26 (13.27)
Employment (Yes) 55 (28.06) 18 (9.18) 73 (37.24)
Disclosure of HIV Status (Yes) 78 (39.80) 50 (25.51) 128 (65.31)
Years since HIV diagnosis 4.10 ± 3.19 (0–15) 2.69 ± 1.72 (0–15) 3.61 ± 2.86 (0–15)
Prescribed ART in admission (Yes) 78 (39.80) 32 (16.33) 110 (56.12)
Years of ART use 3.57 ± 3.12 (0–10) 2.31 ± 1.87 (0–10) 3.14 ± 2.82 (0–15)
ART regimen
 TDF-based regimen 50 (25.51) 15 (7.65) 65 (33.16)
 AZT-based regimen 4 (2.04) 1 (0.51) 5 (2.55)
 LPV/r-based regimen 29 (14.80) 11 (5.61) 40 (20.41)
Presence of comorbidities 98 (50.00) 61 (31.12) 159 (81.12)
 Pneumonia 28 (14.29) 27 (13.78) 55 (28.06)
 Hepatitis 7 (3.57) 2 (1.02) 9 (4.59)
 Tuberculosis 4 (2.04) 4 (2.04) 8 (4.08)
 Diabetes 4 (2.04) 3 (1.53) 7 (3.57)
 Syphilis 5 (2.55) 2 (1.02) 7 (3.57)
 Cancer 6 (3.06) 0 (0.00) 6 (3.06)
 Hypertension 3 (1.53) 0 (0.00) 3 (1.53)
 Chronic Diarrheal 0 (0.00) 2 (1.02) 2 (1.02)
CD4+ T cell count
 0–50 14 (7.14) 27 (13.78) 41 (20.92)
 51–250 62 (31.63) 30 (15.31) 92 (46.94)
 251–500 29 (14.80) 12 (6.12) 41 (20.92)
  > 501 20 (10.20) 2 (1.02) 22 (11.22)
Viral load (RNA)
  < 500 111 (56.63) 68 (34.69) 179 (91.33)
  > 500 14 (7.14) 3 (1.53) 17 (8.67)
Length of in-hospital stay 11.86 ± 8.90 (1–45) 16.15 ± 10.28 (2–56) 13.42 ± 9.62 (1–56)
BMI
  < 17 1 (0.51) 17 (8.67) 18 (9.18)
 17–18.5 8 (4.08) 14 (7.14) 22 (11.22)
 18.5–25 101 (51.53) 40 (20.41) 141 (71.94)
  ≥ 25 15 (7.65) 71 (36.22) 15 (7.65)
Albumin
  < 35 27 (13.78) 40 (20.41) 67 (34.18)
  ≥ 35 98 (50.00) 31 (15.82) 129 (65.82)
Prealbumin
  < 200 62 (31.63) 58 (29.59) 120 (61.22)
  ≥ 200 63 (32.14) 13 (6.63) 76 (38.78)
  1. ART antiretroviral therapy, AZT zidovudine, BMI body mass index, LPV/r lopinavir–ritonavir, TDF tenofovir